H-T Arkenau

Author PubWeight™ 8.53^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.	Ann Oncol	2008	3.44
2	Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?	Br J Cancer	2009	1.44
3	The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.	Br J Cancer	2010	1.14
4	Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.	Br J Cancer	2012	1.06
5	Second primary colorectal cancers (SPCRCs): experiences from a large Australian Cancer Registry.	Ann Oncol	2009	0.86
6	The feasibility of using topotecan, vinorelbine, thiotepa and gemcitabine (TVTG) in adult patients with relapsed/refractory acute lymphoblastic leukaemia/lymphoma.	Leukemia	2008	0.76